QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer
10 Settembre 2024 - 1:00PM
Business Wire
QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce
the appointment of Lee Bowman as Chief Human Resources Officer
(CHRO). In this pivotal role, Bowman leads QuidelOrtho’s human
resources strategy, driving initiatives that bolster a dynamic and
inclusive workplace culture. Bowman reports to Brian Blaser,
President and Chief Executive Officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240910545042/en/
Lee Bowman, Chief Human Resources
Officer, QuidelOrtho (Photo: Business Wire)
Bowman brings over 25 years of experience in human resources
leadership, with a distinguished career that spans key roles in
major industries. Most recently, he served as the Senior Vice
President and Chief People Officer at RadNet, a leading healthcare
technology company, where he led transformative initiatives in
workforce engagement, diversity and inclusion, and leadership
development. His career also includes significant contributions at
Edwards Lifesciences, Levi Strauss & Co., and Target, where he
led high-impact HR strategies that prioritized team development and
organizational growth.
“Lee is an exceptional leader with a deep understanding of how
to align human resources strategies with business objectives,” said
Brian Blaser, President and Chief Executive Officer of QuidelOrtho.
“His expertise in talent development and commitment to fostering an
inclusive, high-performing workplace will be pivotal as we continue
to strengthen our team and drive continued growth.”
As CHRO, Bowman oversees all facets of QuidelOrtho’s human
resources function, including the design and implementation of
strategies across compensation, benefits, recruitment, talent
management, training and employee development.
Bowman holds an MBA from San Diego State University and a
Bachelor of Science from Towson University.
QuidelOrtho is dedicated to advancing diagnostics to power a
healthier future. For more information, please visit
www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook
and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in
vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed – from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its many years of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects and a more informed path is
illuminated for each of us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910545042/en/
Investor Contact: Juliet Cunningham Vice President, Investor
Relations IR@QuidelOrtho.com
Media Contact: D. Nikki Wheeler Senior Director, Corporate
Communications Media@QuidelOrtho.com
Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni QuidelOrtho (NASDAQ:QDEL)
Storico
Da Dic 2023 a Dic 2024